Recap: Spectrum Pharmaceuticals Q3 Earnings

Shares of Spectrum Pharmaceuticals SPPI decreased 1.36% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 22.73% over the past year to ($0.27), which beat the estimate of ($0.35).

Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $50,000.

Guidance

Spectrum Pharmaceuticals hasn't issued any earnings guidance for the time being.

Spectrum Pharmaceuticals hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 04, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/48qdptsb

Price Action

52-week high: $10.57

Company's 52-week low was at $1.74

Price action over last quarter: down 4.62%

Company Profile

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Its other products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA.